Abstract titles reveal some of ASCO’s key datasets.

Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.

The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

Readout of the delayed Galaxies Lung-201 study is due imminently.

When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.

The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.